Trials / Completed
CompletedNCT05653284
A Study of AK130 in Patients With Advanced Malignant Tumors
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AK130 (TIGIT/TGF-β Bifunctional Fusion Protein) in Patients With Advanced Malignant Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AK130 (TIGIT/TGF-β bifunctional fusion protein) in patients with advanced malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK130 | IV infusion, specified dose on specified days. |
Timeline
- Start date
- 2023-02-09
- Primary completion
- 2023-12-12
- Completion
- 2024-05-30
- First posted
- 2022-12-16
- Last updated
- 2024-08-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05653284. Inclusion in this directory is not an endorsement.